

Provided by:



## Lymphoma Tumor Board and Case Conference 2023-2024

Lymphoma Tumor Board and Case Conference 2023-2024 - 4/23/2024

April 23, 2024

4:00 PM - 5:00 PM

<https://pennteam.zoom.us/j/99144157578>

### Target Audience

This program has been designed for DERMATOLOGY, INTERNAL MEDICINE - Hematology, NUCLEAR MEDICINE, INTERNAL MEDICINE - Medical Oncology, RADIATION ONCOLOGY, DERMATOLOGY - Dermatopathology, CLINICAL CYTOGENETICS AND GENOMICS, CLINICAL MOLECULAR GENETICS AND GENOMICS, LABORATORY GENETICS AND GENOMICS, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology, PATHOLOGY - Dermatopathology, PATHOLOGY - Hematopathology, PATHOLOGY - Pathology-Molecular Genetic, RADIOLOGY , RADIOLOGY - Nuclear Radiology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss additional treatment options for lymphoma patients, including those that are not standard of care.
- 2 Describe clinical trials inside and outside of Penn, for which patients may be eligible
- 3 Discuss ongoing standard of care options of lymphoma subtypes
- 4 Discuss some of the complexities surrounding specific cases of diagnosing or classifying lymphoma sub-type
- 5 Discuss multi-disciplinary treatment modalities

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is approved for **1.00** contact hours

UAN Number: JA0000324-0000-24-019-L04-P

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

For more information, please contact

Emeline Chong, Tamiेशia Nixon, Julie Mcdaniel  
(215) 349-8750, (215) 662-4074, (267) 970-8367

[Emeline.Chong@uphs.upenn.edu](mailto:Emeline.Chong@uphs.upenn.edu), [Tamiेशia.Nixon@pennteam.upenn.edu](mailto:Tamiेशia.Nixon@pennteam.upenn.edu), [mcdjulie@upenn.edu](mailto:mcdjulie@upenn.edu)

Check your transcript online at <https://upenn.cloud-cme.com>

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
John Plastaras, MD	Other Planning Committee Member	Nothing to disclose - 02/21/2024
Dale M Frank, MD	Other Planning Committee Member	Nothing to disclose - 09/06/2023
Arthur M Feldman, MD	Other Planning Committee Member	Nothing to disclose - 03/08/2024
Sunita D. Nasta, MD	Other Planning Committee Member	Grant or research support-Genentech   Grant or research support-Takeda Pharmaceuticals   Grant or research support-AbbVie, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co - 07/14/2023
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose - 07/11/2023
David Henry, MD	Other Planning Committee Member	Nothing to disclose - 12/05/2023
Daniel Landsburg	Other Planning Committee Member	Grant or research support-Calithera   Honoraria-Novartis (Advanced Health Media) (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis (Advanced Health Media) (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Calithera (Relationship has

		ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Epizyme (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-ADCT (Relationship has ended)  Speakers Bureau-ADCT  Speakers Bureau-Novartis (Advanced Health Media) (Relationship has ended) - 12/05/2023
Mitchell Hughes, PharmD	Pharmacy Planner	Advisor-AbbVie, Inc. (Relationship has ended)  Grant or research support-HOPA/Acerta Pharma  Advisor-Karyopharm (Relationship has ended)  Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) - 06/21/2023
Ellen Napier, CRNP, MSN	Nurse Planner	Other: travel support-Genentech  Other: travel to investigator's meeting-Genmab (Relationship has ended) - 12/06/2023
Michael LaRiviere, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 02/26/2024
Danielle Land, CRNP	Co-Director	Speakers Bureau-Astra Zeneca Pharmaceuticals  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Beigene  Speakers Bureau-Janssen Pharmaceuticals (J&J)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J) - 06/21/2023
Gabriel C Caponetti, MD	Other Planning Committee Member	Consulting Fee-Gerson Lehrman Group  Consulting Fee-DAVA Oncology - 09/29/2023
Siddharth Bhattacharyya, MD	Other Planning Committee Member	Nothing to disclose - 03/26/2024
Stephen J. Schuster, MD	Other Planning Committee Member	Consulting Fee-Genentech  Consulting Fee-AstraZeneca  Consulting Fee-BeiGene (Relationship has ended)  Honoraria-Takeda Pharmaceuticals (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Caribou Biosciences  Grant or research support-Genentech  Grant or research support-Genentech  Consulting Fee-Genmab  Consulting Fee-Incyte Corporation  Consulting Fee-Morphosys  Consulting Fee-Janssen Pharmaceuticals (J&J)  Consulting Fee-Kite Pharma  Consulting Fee-Novartis / Amgen  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis / Amgen  Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)  Consulting Fee-Celgene Corporation  Consulting Fee-Mustang Biotech

		(Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Legend Biotech   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Fate Therapeutics   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nordic Nanovector (Relationship has ended) - 01/26/2024
Adam Bagg, MD	Other Planning Committee Member	Nothing to disclose - 01/10/2024
Elise Chong, MD	Other Planning Committee Member	Consulting Fee-Novartis / Amgen (Relationship has ended)   Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Consulting Fee-Gilead Sciences, Inc (Relationship has ended)   Consulting Fee-Beigene (Relationship has ended)   Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended)   Grant or research support-AbbVie, Inc.   Grant or research support-Genentech - 12/18/2023
Stefan K Barta, MD	Other Planning Committee Member	Consulting Fee-Affimed (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)   Consulting Fee-Seattle Genetics (Relationship has ended)   Honoraria-Acrotech   Consulting Fee-Daiichi Sankyo (Relationship has ended)   Honoraria-Kyowa Kirin - 01/22/2024
Jakub Svoboda, MD	Co-Director	Grant or research support-Incyte Corporation   Consulting Fee-Incyte Corporation (Relationship has ended)   Grant or research support-Merck & Co (Relationship has ended)   Grant or research support-Pharmacyclics   Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Grant or research support-Bristol-Myers Squibb   Grant or research support-TG Therapeutics (Relationship has ended)   Consulting Fee-Seattle Genetics (Relationship has ended)   Grant or research support-Seattle Genetics (Relationship has ended)   Consulting Fee-Astra Zeneca Pharmaceuticals   Grant or research support-Astra Zeneca Pharmaceuticals   Consulting Fee-Atara   Consulting Fee-Adaptive   Grant or research support-Adaptive   Grant or research support-Gilead Sciences, Inc   Consulting Fee-Genmab (Relationship has ended) - 01/30/2024
Rachel Lundberg, PA-C	Physician Assistant Planner	Nothing to disclose - 10/11/2023
Jordan Carter, MD	Faculty, Other Planning Committee Member	Nothing to disclose - 01/15/2024

Shivani Bakhshi, DO	Other Planning Committee Member	Nothing to disclose - 09/22/2023
---------------------	------------------------------------	----------------------------------

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected